NCT01242631View on ClinicalTrials.gov

Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Testicular CancerGerm Cell Cancer
Interventions
DRUG

Everolimus

Everolimus 10 mg orally per day.

Trial Locations (8)

10967

Vivantes Klinikum am Urban, Berlin

20246

Universitatsklinikum Hamburg-Eppendorf, Hamburg

24105

Universitatsklinikum Schieswig-Holstein - Campus Kiel, Kiel

30625

Hannover Medical School, Hanover

35043

Universitatsklinikum Marburg, Marburg

45122

Universitatsklinikum Essen, Essen

72076

Universitatsklinikum der Eberhard-Karls-Universitat Tübingen, Tübingen

81545

Klinikum Harlaching München, München

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Hannover Medical School

OTHER

NCT01242631 - Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer | Biotech Hunter | Biotech Hunter